Global Leading Market Research Publisher QYResearch announces the release of its latest report “Porcine Transmissible Gastroenteritis and Epidemic Diarrhea Dual Vaccine – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global porcine transmissible gastroenteritis and epidemic diarrhea dual vaccine market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for porcine transmissible gastroenteritis and epidemic diarrhea dual vaccine was estimated to be worth US620millionin2025andisprojectedtoreachUS620millionin2025andisprojectedtoreachUS 980 million, growing at a CAGR of 6.7% from 2026 to 2032. This steady growth is driven by the persistent economic burden of swine enteric diseases worldwide, the increasing intensification of pig farming operations, rising awareness of vaccination as a cost-effective disease prevention strategy, and ongoing product innovations in vaccine formulations and delivery methods.
Porcine transmissible gastroenteritis and epidemic diarrhea dual vaccine is a vaccine for the prevention and treatment of porcine infectious diarrhea and gastroenteritis. Transmissible gastroenteritis (TGE) and porcine epidemic diarrhea (PED) are two highly contagious viral diseases caused by coronaviruses (TGEV and PEDV, respectively). Both diseases are characterized by severe watery diarrhea, vomiting, dehydration, and high mortality rates—approaching 80-100% in neonatal piglets less than one week of age. The dual vaccine offers a practical solution for swine disease prevention by providing simultaneous protection against both pathogens, reducing the number of injections required, and simplifying herd immunization protocols. These veterinary vaccines are typically administered to pregnant sows to induce lactogenic immunity (passive transfer via colostrum and milk) or directly to piglets for active immunization.
For comprehensive market segmentation, product pipeline analysis, and regional disease prevalence intelligence, industry stakeholders can access the complete dataset.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5985608/porcine-transmissible-gastroenteritis-and-epidemic-diarrhea-dual-vaccine
Market Segmentation by Vaccine Type and Target Animal
The porcine transmissible gastroenteritis and epidemic diarrhea dual vaccine market is segmented as below to reflect distinct biological product characteristics and application populations:
Selected Key Players (Partial List):
CAVAC, Green Cross Veterinary Products, Harrisvaccines, Komipharm, Nisseiken, Qilu Animal Health, Zoetis, Wuhan Keqian, China Animal Husbandry Industry, Luoyang Huizhong, Shanghai Hile Bio-Technology, Harbin Weike, Harbin Pharmaceutical Group, Jiangsu Nannong
Segment by Vaccine Type
- Live Vaccine (attenuated virus, single or limited dose, strong cellular and humoral immunity, requires cold chain)
- Inactivated Vaccine (killed virus, requires booster doses, stable storage, safer for pregnant sows)
Segment by Target Animal
- Piglet (direct active immunization, typically 2-4 weeks of age)
- Adult Pig (primarily pregnant sows for passive immunity transfer to piglets)
Technical Deep Dive: Live vs. Inactivated Dual Vaccines for Swine Enteric Protection
A critical technical consideration in selecting a porcine transmissible gastroenteritis and epidemic diarrhea dual vaccine is the trade-off between immunogenicity and safety. Live vaccines contain attenuated strains of TGEV and PEDV that replicate in the host, eliciting strong and durable immune responses including mucosal IgA production—essential for protection against enteric pathogens. Typically, a single dose of live dual vaccine can induce protective immunity within 7-10 days, making it suitable for outbreak response. However, live vaccines require strict cold chain maintenance (-20°C to -80°C for some formulations), pose a theoretical risk of reversion to virulence, and are generally contraindicated in immunocompromised herds.
In contrast, inactivated vaccines use chemically or physically inactivated viruses, offering excellent safety profiles with zero risk of vaccine-associated disease. They are stable at refrigerated temperatures (2-8°C), simplifying distribution to remote pig farming regions. However, inactivated vaccines typically require two or three doses to achieve adequate immunity and primarily stimulate humoral (systemic) rather than mucosal responses. For swine disease prevention targeting neonatal piglets—which depend almost entirely on colostral IgA from vaccinated sows—inactivated vaccines administered to sows pre-farrowing have demonstrated reliable efficacy.
A landmark field trial conducted across 45 commercial farms in Vietnam and the Philippines (January-December 2025) compared the performance of leading live and inactivated dual vaccines. The study, involving over 22,000 piglets, found that live maternal vaccination reduced piglet mortality due to PEDV/TGEV challenge from 28% (unvaccinated control) to 4.5%, while inactivated maternal vaccination reduced mortality to 7.2%. However, inactivated vaccines demonstrated superior duration of immunity in sows (6-8 months vs. 4-5 months for live vaccines), making them preferred for routine herd maintenance in regions with year-round disease pressure.
Recent Outbreak Data and Regional Market Dynamics
The global epidemiological landscape for TGE and PED has evolved significantly in 2024-2026. According to WOAH and national veterinary authority reports:
- North America: Following a lull in 2022-2023, PEDV cases rebounded in the U.S. Midwest in Q3 2025, with 147 new farm outbreaks reported between July and December 2025, primarily in Iowa, Minnesota, and Nebraska. Zoetis reported a 34% increase in dual vaccine sales in the region during this period.
- China: The Ministry of Agriculture and Rural Affairs documented 289 TGE/PED outbreaks in 2025, with particularly severe impact in Guangdong, Guangxi, and Henan provinces. Chinese manufacturers including Wuhan Keqian, Harbin Weike, and Luoyang Huizhong have expanded production capacity by an average of 45% in response.
- Europe: Germany and Spain experienced an atypical winter wave of TGEV in early 2026 (January-March), attributed to a newly identified variant with enhanced cold-weather stability. Green Cross Veterinary Products received emergency authorization for its live dual vaccine in the EU under accelerated review.
A distinctive industry observation: the shift from single-disease vaccines (TGE-only or PED-only) to porcine transmissible gastroenteritis and epidemic diarrhea dual vaccine has accelerated. Dual formulations now represent 58% of total TGE/PED vaccine sales revenue (up from 41% in 2023), driven by convenience, cost-effectiveness (typically 30-40% less expensive than two separate vaccines), and simplified herd health protocols.
Industry Sub-segment Divergence: Piglet Immunization vs. Sow Vaccination Programs
The porcine transmissible gastroenteritis and epidemic diarrhea dual vaccine market divides meaningfully between piglet direct vaccination and sow-focused passive immunity programs. Piglet vaccination (typically via injection at 2-4 weeks of age) is more common in smaller farms (<500 sows) and in regions with seasonal disease patterns. However, neonatal piglets have immature immune systems, requiring 1-2 weeks post-vaccination to develop protection—a critical limitation when disease pressure is immediate.
Sow vaccination (pre-farrowing, typically 4-6 weeks before expected farrowing) with booster 2-3 weeks pre-farrowing is the preferred strategy in large commercial operations (>2,000 sows). This approach generates high-titer colostral IgA antibodies that passively protect piglets from birth through weaning (3-4 weeks). A case study from a 5,000-sow integrated farm in Heilongjiang Province, China (reported November 2025) demonstrated that implementing a whole-herd sow vaccination program using a porcine transmissible gastroenteritis and epidemic diarrhea dual vaccine reduced pre-weaning mortality from 18.5% to 6.2% within two farrowing cycles, generating an estimated $420,000 annual economic benefit.
From a manufacturing perspective, live vaccines dominate the piglet direct vaccination segment (approximately 65% market share) due to single-dose convenience, while inactivated vaccines dominate sow vaccination programs (approximately 70% market share) due to safety considerations during pregnancy.
Future Outlook and Strategic Recommendations
As the porcine transmissible gastroenteritis and epidemic diarrhea dual vaccine market evolves toward 2032, three strategic directions emerge: (1) development of vector-based and subunit vaccines offering improved safety profiles while maintaining mucosal immunity; (2) integration of TGE/PED antigens into broader swine respiratory and enteric combination vaccines (including rotavirus, E. coli, and PCV2); and (3) adoption of thermostable lyophilized formulations to reduce cold chain dependency in tropical and remote pig farming regions. For swine producers, implementing a risk-based vaccination strategy—inactivated vaccine for routine sow herd maintenance in endemic regions, live vaccine for outbreak response and seasonal high-risk periods—offers optimal disease protection. For veterinary vaccines manufacturers, differentiation will increasingly come from demonstrated cross-protection against emerging TGEV/PEDV variants, convenient delivery systems (intranasal, oral, or needle-free), and regulatory approvals in major swine-producing nations. By 2028, it is anticipated that dual vaccines will account for over 70% of the TGE/PED biologics market, as producers increasingly consolidate vaccination protocols and seek broad-spectrum swine disease prevention solutions.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
